February 2026 in “World Academy of Sciences Journal” This case report describes a rare occurrence of primary cutaneous diffuse large B-cell lymphoma, not otherwise specified (PCDLBCL-NOS) on the scalp of a 45-year-old female, highlighting its unusual presentation and the initial treatment response but also noting severe subsequent complications.
1 citations
,
January 2009 in “The Open Dermatology Journal” This case report describes a patient with diffuse large B cell lymphoma who experienced temporary Beau’s lines and onycholysis while undergoing R-CHOP chemotherapy, which resolved two months after treatment ended.
9 citations
,
January 2018 in “Acta Clinica Croatica” This review suggests that bendamustine, alone or in combination, shows effectiveness in treating indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia, with recent studies highlighting its benefits especially in combination therapies, while balancing efficacy with a favorable toxicity profile.
March 2025 in “OncoTargets and Therapy” This study found that in circulating tumor cells from non-invasive liquid biopsies, the GG genotype of the CYP3A5 A6986G affects longer disease-free survival in DLBCL patients, highlighting the significance of circulating biomarkers for prognostic evaluation.
September 2012 in “International Current Pharmaceutical Journal” In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.